Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to...